Search

Search bills, members, committees and pages...

H 676

Vermont HouseIn House Committee

Summary

H 676, an act relating to maintaining patient access to animal-derived thyroid medications, was introduced in the House on Jan 14, 2026 by Rep. Gregory Burtt (R) with 2 co-sponsors. It was referred to Health Care, and last saw action on Jan 14, 2026: Read first time and referred to the Committee on Health Care.


Record

Text

H 676 has 2 co-sponsors.

h676/introduced.txt
BILL AS INTRODUCED H.676
2026 Page 1 of 2
H.676
Introduced by Representatives Burtt of Cabot, Bosch of Clarendon, and
Hooper of Burlington
Referred to Committee on
Date:
Subject: Health; prescription drugs; animal-derived thyroid medications;
desiccated thyroid extract
Statement of purpose of bill as introduced: This bill proposes to direct the
Office of Professional Regulation to consider ways to ensure that animal-
derived thyroid medications continue to be available to Vermonters. It would
require the Office of Professional Regulation and the Department of Financial
Regulation to implement all feasible options and would require the Office to
report to the General Assembly with findings, recommendations, and any
options that would require legislative action.
An act relating to maintaining patient access to animal-derived thyroid
medications
It is hereby enacted by the General Assembly of the State of Vermont:
Sec. 1. MAINTAINING PATIENT ACCESS TO ANIMAL-DERIVED
THYROID MEDICATIONS; REPORT
VT LEG #386207 v.1
BILL AS INTRODUCED H.676
2026 Page 2 of 2
(a) The Office of Professional Regulation, in consultation with the
Department of Financial Regulation; representatives of health care
professionals, of health insurers, and of patients with hypothyroidism and other
thyroid-related disorders; and other interested stakeholders, shall consider all
options for ensuring that animal-derived thyroid medications, including
desiccated thyroid extract, continue to be available to patients in Vermont for
whom those medications are more effective or better tolerated than synthetic
thyroid medications. The Office of Professional Regulation and the
Department of Financial Regulation shall promptly implement all feasible
options that do not require legislative action.
(b) On or before January 15, 2027, the Office of Professional Regulation
shall report its findings and recommendations, including options already
implemented and any that require legislative action, to the House Committee
on Health Care and the Senate Committee on Health and Welfare.
Sec. 2. EFFECTIVE DATE
This act shall take effect on passage.
VT LEG #386207 v.1

An act relating to maintaining patient access to animal-derived thyroid medications

Sponsors

Rep. Gregory Burtt (R) sponsors H 676, and 2 members have co-sponsored it.

Committees

H 676 went before 1 committee: Health Care.

Health Care
Health Care
Referred to · Jan 14, 2026 · 73 Bills

History

H 676 has taken 1 action since Jan 14, 2026.

ChamberAction
Jan 14, 2026
House
Read first time and referred to the Committee on Health Care

Votes

H 676 has not gone to a roll call.


Source: legislature.vermont.gov · legiscan.com